(EVGN) Evogene Ltd. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
Go Beyond the Preview—Access the Full Ansoff Matrix Analysis
This Evogene Ltd. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification in one concise framework. This page includes a real preview/sample of the analysis so you can review style and substance before buying; purchase the full version to get the complete ready-to-use report.
Market Penetration
CPB-led co-development with BASF, Corteva and Bayer
Evogene’s CPB-led co-development with BASF SE, Corteva and Bayer is a clear market penetration play: it uses existing licensing ties to push Evogene’s Computational Predictive Biology into current seed and crop-protection channels. With three global ag leaders already in the network, Evogene can widen adoption without building a new sales stack. The logic is simple: sell deeper into markets already served.
Priority crop concentration
Evogene Ltd. focuses on corn, soybean, wheat, rice, and cotton, five crops that dominate global acreage and spending; USDA data puts 2025-26 world corn output near 1.3 billion metric tons and soybean output near 420 million tons. That scale supports market penetration because demand is already deep. Its seed trait, crop chemical, and biological programs fit these same large segments, so each win can scale fast.
Multi-division platform leverage
Evogene’s 3 divisions—Agriculture, Human Health, and Industrial Applications—can use 1 CPB discovery platform to reach more buyers inside current markets. That raises cross-selling chances and lowers the cost of serving each segment because the same engine supports multiple customer needs. In market penetration terms, one platform can deepen share without building a new stack for every division.
US, Israel and Brazil operating base
Evogene Ltd. has a three-country operating base in the US, Israel, and Brazil, which makes market penetration a near-term play in familiar geographies. The main upside is deeper commercialization and more partner-led activity in these same markets, rather than a new-country push. Its wider international footprint also gives it more room for local execution.
- 3 core operating countries
- Focus on deeper commercialization
- Partner activity can scale faster
- Other markets widen execution options
Canonic-Cannbit medical cannabis channel
Canonic Ltd. and Cannbit Ltd. give Evogene Ltd. a direct medical cannabis route in an existing product line, so this is market penetration, not a new-category push. It deepens reach in a regulated niche where Cannbit already sells, which can lift usage without building a new channel from scratch.
For Evogene Ltd., the value is faster access, lower go-to-market friction, and more repeat demand in medical cannabis. The partnership is a channel play that can widen patient uptake and strengthen share in the same market.
- Existing cannabis line, not new category
- Direct route to medical users
- Lower channel-build cost
- Stronger share in same market
Evogene Expands Fast in Major Crops with BASF, Corteva, and Bayer
Evogene Ltd.’s market penetration is driven by deeper use of its CPB platform with BASF SE, Corteva, and Bayer in existing seed and crop-protection channels. With 2025-26 world corn output near 1.3 billion metric tons and soybeans near 420 million tons, its focus on major crops can scale fast. The goal is simple: win more share in markets it already serves.
| Signal | Data |
|---|---|
| Core crops | corn, soybean, wheat, rice, cotton |
| Major 2025-26 output | corn 1.3bn tons; soybeans 420m tons |
| Key partners | BASF SE, Corteva, Bayer |
What is included in the product
Detailed Word Document
Analyzes Evogene Ltd.’s growth strategy through market and product expansion options in the Ansoff Matrix
Editable Excel File
Provides a clear, at-a-glance Ansoff Matrix for Evogene Ltd. to speed growth strategy decisions.
Reference Sources
Provides a concise, traceable bibliography linking each Ansoff growth path for Evogene Ltd. to primary, credible sources for fast verification and defensible decisions.
Market Development
International rollout beyond core geographies
Evogene Ltd. already operates in the United States, Israel and Brazil, so international rollout is a fit for its existing global model. Extending its CPB-based solutions into new countries can reuse the same platform, partners and field-validation work, which lowers launch risk. For market development, the key test is whether new regions can match the adoption seen in Evogene Ltd.'s current markets.
Agricultural expansion into new crop markets
Evogene Ltd.’s agriculture pipeline already spans 5 major crops: corn, soybean, wheat, rice and cotton. That makes market development a practical Ansoff move, because the same product concepts can be pushed into new crop geographies without redesigning the core platform. With global crop demand still broad and fragmented, even one validated trait or biological can scale across multiple farming regions.
Partner-led entry into new regions
Evogene Ltd. uses partner-led entry to reach new regions through BASF, Corteva and Bayer, three firms that already sell across global farm markets. BASF Crop Protection booked about €9.8 billion in 2024 sales, Corteva about $17.4 billion, and Bayer Crop Science about €22.3 billion, so their channels can open markets Evogene has not built on its own. Distribution and licensing are the clearest path for faster regional access and lower launch risk.
Human health programs for broader territories
Evogene Ltd. can use market development to take its human health programs in immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections into new countries and care systems without changing the core science. The case is strong: cancer caused about 9.7 million deaths in 2022, and antimicrobial resistance was linked to 1.27 million deaths in 2019.
- Same pipeline, new geographies.
- Fits oncology, GI, and AMR demand.
- Scale via local trials and partners.
That route can raise addressable patients while keeping R&D focused on one therapeutic set.
Industrial raw-material applications abroad
Evogene Ltd.’s industrial raw-materials work uses castor bean seed enhancement to lift yield and quality, and castor seed typically contains about 45% to 55% oil. That lets the same platform target new buyers in chemicals, lubricants, and bio-based inputs beyond current core locations, widening addressable demand for castor-based raw materials.
Higher seed oil content supports scale.
One platform can serve multiple markets.
Geographic reach can expand demand.
Evogene’s Same Platform, Bigger Global Reach
Evogene Ltd. can grow by taking its existing crop and health platforms into new countries, using the same science, partners and validation work. Partner channels matter: Bayer Crop Science posted about €22.3 billion in 2024 sales, Corteva about $17.4 billion, and BASF Crop Protection about €9.8 billion. Same platform, wider reach.
| Area | Latest data | Market role |
|---|---|---|
| Crop partners | €22.3bn, $17.4bn, €9.8bn | Fast regional access |
| Human health | 9.7m cancer deaths; 1.27m AMR deaths | New patient markets |
| Castor oil | 45%-55% oil | New industrial buyers |
Full Version Awaits
Evogene Ltd. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix for Evogene Ltd., ready for immediate use.
Product Development
New seed traits pipeline
Evogene Ltd. uses its agriculture division to push new seed traits for the same crop customers, so this is classic product development in the Ansoff Matrix. The CPB discovery platform helps screen and refine trait candidates faster, which matters because trait R&D can take years and many programs fail before field validation. This path can lift share in existing markets without needing a new crop base.
Ag-chemical and biological product creation
Evogene Ltd. uses its digital discovery platform to create new ag-chemical and biological crop inputs for existing farm markets, which is classic product development in the Ansoff Matrix. The crop protection and biologicals market keeps expanding, with biological crop protection projected to reach about $20 billion by 2027, so new products can tap real demand without changing the customer base. This fits Evogene’s model: design, screen, and guide new life-science products faster and with lower lab-to-field risk.
Microbiome-based treatment pipeline
Evogene Ltd.’s human health unit is extending its current pipeline into human microbiome-based treatments, with new products aimed at immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. This is a direct fit with its existing health focus, so it raises adjacency without needing a new business model. The microbiome field is already in clinical development, with programs spanning Phase 2 and Phase 3, which supports the case for faster pipeline reuse.
Castor bean seed enhancement
Evogene’s castor bean seed enhancement fits product development: it upgrades an existing raw material line with better seed traits for industrial users. Castor seeds typically contain about 45% to 55% oil, so even small yield or quality gains can lift downstream value. In 2025, Evogene kept this as a focused innovation lane inside its industrial biotech work.
- Existing market, new seed offer
- Targets industrial-grade quality
- High oil content supports upside
Medical cannabis offerings through Canonic
Evogene Ltd.'s medical cannabis work through Canonic Ltd. and its Cannbit Ltd. tie-up is a product development move in the Ansoff Matrix: new products, same medical-use market. That fits a low-friction expansion path because it builds on channels the Company already serves.
For FY2025, the most decision-useful read is whether Canonic’s product pipeline can raise share in existing medical cannabis demand without needing a new market build.
- Same market, new medical products
- Uses Canonic and Cannbit access
- Limits go-to-market risk
Evogene Expands Products, Not Markets, to Cut Risk
Evogene Ltd.’s product development play is clear in FY2025: it keeps the same ag and health markets, but adds new traits, biologicals, and microbiome products. That fits the Ansoff Matrix, and it lowers market-entry risk because the customer base is already there.
| FY2025 lane | Data point | Why it matters |
|---|---|---|
| Ag and health | New products for existing users | Raises share without new market build |
Diversification
Agriculture to human health expansion
Evogene’s move from crop discovery into human health is classic diversification: it now serves two very different markets, with the same CPB engine powering both. That shared platform lowers retooling risk, while the shift from agriculture to therapeutic development widens its addressable market and reduces reliance on crop-cycle demand.
Microbiome therapeutics in oncology GI and AMR
Evogene Ltd.'s human health arm is a clear diversification move: it extends beyond agriculture into microbiome therapeutics for oncology, gastrointestinal disease, and antimicrobial-resistant infections. That shifts the company into new patient markets and product types, where global AMR alone is linked to about 1.27 million deaths each year. It also broadens revenue options beyond seed and crop tech.
Industrial castor bean platform
Evogene’s industrial castor bean platform is a clear diversification move in Ansoff terms: it opens a non-agricultural, non-human-health line with a separate customer base. Castor bean seed enhancement targets industrial raw-material demand, and more than 90% of castor output already goes to industrial uses, not food. That gives Evogene exposure to a distinct end market with different pricing and demand drivers.
Medical cannabis via Canonic
Evogene’s medical cannabis work through Canonic Ltd. and Cannbit Ltd. adds an adjacent market to its core crop-trait and microbiome focus. That moves the company from one life-science lane into a broader mix of seed-tech, microbial, and cannabis product work. In Ansoff terms, this is diversification: new products in a new or lightly related market.
It can spread revenue risk, but it also raises execution and regulatory risk. The bigger point is simple: Evogene is widening its business mix beyond core ag-tech.
- Adjacent market added: medical cannabis
- Subsidiaries: Canonic Ltd., Cannbit Ltd.
- Strategy: diversification in Ansoff Matrix
- Effect: broader life-science exposure
Microbes small molecules and genetic components
Evogene’s CPB platform diversifies the company by sourcing solutions from microbes, small molecules, and genetic components, so one discovery engine can feed several life-science markets. That breadth matters because it spreads R&D risk across product types and lets Evogene pursue ag-biologicals, human health, and other adjacent uses from one core platform. This is the main diversification lever in the portfolio.
- One platform, multiple product classes
- Supports cross-market expansion
- Reduces single-asset dependence
Evogene’s One Engine Powers Multiple Markets
Evogene Ltd.’s diversification is real: it uses its CPB platform across ag-biologicals, human health, castor, and cannabis, so one engine feeds several end markets. That lowers dependence on crop cycles, but it also raises execution and regulatory risk. The clearest proof is the move into human health and cannabis, both outside core ag-tech.
Global AMR is linked to about 1.27 million deaths a year, and more than 90% of castor output goes to industrial uses, not food.
| Area | Signal | Data |
|---|---|---|
| Human health | New market | AMR deaths: 1.27m/year |
| Castor | Industrial end market | >90% industrial use |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.